Member Info for marik

Folks we are going off tangent. Let's keep to the point and not discuss other shares like NCYT it is really not relevant whatever the tangential link might be. So continuing our discussion on Affidx betters Vatic Health:

"Abingdon Health rose 38% off of the news from Vatic. I can't take credit for this as some really good research from our crew here at the LSE shows that Vatic Health Ct value is <25 (10,000 - 50,000 copies per ml). Vatic are hoping for 100m tests per year, that's approx 8.3m tests a month.

Avacta is able to detect at far higher than a Ct of 25. If the crew members on the LSE are correct Avacta could be selling far higher numbers very soon. (Even if the tests are similar, this bodes well). It's good news over all as I suspected many companies are anticipating that the use of lateral flow tests will continue well into 2022/2023."

I believe that 8.3M tests per month are reasonable in terms of sales and as a superior quality test Avacta are in a prime position to benefit. Could be an interesting week ahead with Abingdon going up 38%, once the penny drops, this will have a rerate on Avacta - is it time for us to take the plunge? It's getting very risky for the shorts? After reasoned opinion, my view is yes to both and as such I have changed my opinion to a "Strong Buy"!

"now quite dated" - so not relevant. Great, we can move on.

@poirot I agree with your view that "#AVCT has a massive opportunity ahead of it to disrupt the massive Chemotherapy market with the Precision platform". I can add that this could become worth in excess of £6Bn for Avacta and if not a lot more. Combined with the therapeutics arm, this could go well in excess of the £20 per share that was initially predicted.

I see that the shorting crew are chasing my every post, for that I thank you. But please those who are shorting, do your own research and be responsible.

Thanks @AgentB, I believe that was an earlier study with fewer n values relying on data from earlier in the pandemic. The paper I've referenced provides a more comprehensive view; it analysed testing data from 139,164 close contacts of 95,716 people infected with SARS-CoV-2.

On the note of LG Chem being a potential acquirer, this is certainly a possibility.

I really wouldn't want to be shorting this right now or out of it, what with HUA round the corner, LG Chem in the pipeline, AVA6000 clinical trial, the news from Vatic, Affidx production already at 1 million and hitting 2-3 million shortly and now we find out that vaccines are good, but their ability to stop transmission diminishes quickly with time.

Have to agree with the half-life comments, Affimer XT works really well and it does de-risk everything - very important and very over looked.

We are all aware that the Delta variant is quite nasty, but recent research shows how vaccines are not as great at reducing transmission as we originally thought. Covid vaccines cut the risk of transmitting Delta, but not for long. Delta variant is more infectious than alpha and secondly, it's onward transmission is almost double. Literally 3 months after being double vaccinated, the chances of transmitting on the delta variant was on par with those who are unvaccinated [1].

This is an unfortunate situation for many of us, but really emphasises that vaccines should be combined more effectively with testing and therapeutics to gain some control of the pandemic. Avacta is in a prime position to form part of the worlds testing regimen, but this looks like a long haul.

1. https://www.nature.com/articles/d41586-021-02689-y

Does anyone know if Sir Al will be doing video Q&A with VOX?

If you can't read don't respond. I was referring to time, but thanks for attempting.

This statement by you really tells me where you and your crew stand. If were not aware humans and mice are mammalian (I wouldn't be surprised if you have a batch of non-mammalian mouse cells lying around).

"but if human mammalian cells and mouse mammalian cells behave similarly"

"I agree Avacta looks like a really hopeful investment..."

Firstly, the personal attacks make you sound like a child and I doubt you think of Avacta in a positive way. Unless your name is Charles and you're my accountant I don't think it's wise for me to be taking advice from the crew. You are also lacking understanding of the basics which is funny considering you messed up on Vatic. Combined together you are coming across as very desperate.

Enjoy your tea.

I am not sure @D-Geeman, I like the concept for may items, but feel that cutting edge tech would come across as slightly gimmicky if endorsed. I think Avacta have done the right thing and mentioned the link, but haven't gone beyond that, it adds an element of professionalism.

Thanks Poirot. I think your point regarding LG Chem is very true it has been largely undervalued. Sometimes there is a delay from the news to the share price rise and I think this is one of those occasions.

"Almost certainly part of the standard T&C of an elite sports team / brand that they will not permit association without prior approval."

Absolutely.

Oh look the tag team from the shorting crew is here.

Hi guys, thanks for the look up, really appreciate it.

AgentB I have seen it and I'm not a huge fan on passports. But whoever the Government PR person is needs to take a course. They describe it as "proposed certification regime".

Double vaccination wears off quite rapidly and without a booster jab or a 2 month expiry time stamp the passport idea is not great.

The use of lateral flow tests is likely to be long term. We've established that the COVID-19 vaccine protective effect is relatively small, and dwindles alarmingly at three months after the receipt of the second shot.

In all I see governments around the world going for vaccine boosters and also testing to remain part of the process.

No I agree gje it's not blanket coverage. I've heard of them before and I believe this board has already discussed how their test isn't that great.

Vatic being picked up by the news because it creates headlines and a nice story. Their website etc is very amateur, but I like their determination. What is even more positive is that they are highlighting the use of lateral flow tests and the need for them for a long time to come.

Was it this post that has caused you anxiety?

"Abingdon Health rose 38% off of the news from Vatic. I can't take credit for this as some really good research from our crew here at the LSE shows that Vatic Health Ct value is <25 (10,000 - 50,000 copies per ml). Vatic are hoping for 100m tests per year, that's approx 8.3m tests a month.

Avacta is able to detect at far higher than a Ct of 25. If the crew members on the LSE are correct Avacta could be selling far higher numbers very soon. (Even if the tests are similar, this bodes well). It's good news over all as I suspected many companies are anticipating that the use of lateral flow tests will continue well into 2022/2023.

Could be an interesting week ahead with Abingdon going up 38%, once the penny drops, this will have a rerate on Avacta - is it time for us to take the plunge?"